This article is more than 5 years old. Information may no longer be current.
IOP decrease maintained with Xen45
Click Here to Manage Email Alerts
SAN FRANCISCO — Decrease in IOP as well as medication burden was sustained over a 12-month period in eyes implanted with the Xen45 gel stent, according to a poster presented at the American Glaucoma Society annual meeting.
Davinder S. Grover , MD, MPH, and colleagues conducted a retrospective study evaluating surgical outcomes after Xen45 (Allergan) implantation in patients at a single glaucoma subspecialty practice since the FDA approval of the device in 2016 for surgical management of refractory glaucoma.
The gel stent was implanted in one eye of each of 207 patients: 172 (83.1%) with the Xen45 alone and 35 (16.9%) with the Xen45 plus phacoemulsification, according to Grover. Mean IOP at baseline was 20.1 mm Hg.
Mean IOP was reduced statistically significantly at each time point measured: day 1, week 1, and months 1, 3, 6 and 12 (all P < .001). Mean decrease in IOP in all eyes was 5.9 mm Hg, and mean decrease in medications was 2.1. The difference in medication burden was also statistically significant at all time points measured (P < .001).
Stage of disease affected outcomes, with a greater likelihood for later need for needling and/or reoperation in patients with preoperative IOP of 21 mm Hg or more. Postoperatively, needling with mitomycin C was done in 70 eyes (34%), and 36 of those eyes underwent further operation.
Gel stent erosion necessitated removal of the Xen45 in three eyes. – by Patricia Nale, ELS
Reference:
Grover DS, et al. A retrospective study evaluating Xen45 surgical outcomes at a single subspecialty glaucoma practice, post-FDA approval. Presented at: American Glaucoma Society annual meeting; March 14-17, 2019; San Francisco.
Disclosure: Grover reports he is a consultant and speaker for Allergan. The study was supported by a research grant from Allergan.